Alexandre Bazinet, M. D.

Peer-Reviewed Articles

1. Kadia TM, Jen WY, Bataller A, Bazinet A, Borthakur G, Jabbour E, Qiao W, Short NJ, Takahashi K, Issa GC, DiNardo CD, Montalban-Bravo G, Pemmaraju N, Tran A, Bharathi V, Loghavi S, Alousi AM, Popat U, Daver NG, Ravandi F, Kantarjian HM. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia. Am J Hematol, 2025. e-Pub 2025. PMID: 40401707.
2. Bataller A, Goulart HE, Issa GC, DiNardo CD, Daver N, Kadia T, Bazinet A, Bouligny IM, Senapati J, Haddad FG, Borthakur G, Sasaki K, Short NJ, Yilmaz M, Montalban-Bravo G, Tang G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian H, Jabbour E. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia, 2025. e-Pub 2025. PMID: 40346311.
3. Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A, Gauthier N, Short N, Bonnet S, Sasaki K, Khalife-Hachem S, Swaminathan M, Micol JB, Pasquier F, Marzac C, Roos-Weil D, Pascal L, Daver N, Kadia T, Bouscary D, Ravandi F, Pages A, Kantarjian H, De Botton S, DiNardo C. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood Cancer J 15(1):68, 2025. e-Pub 2025. PMID: 40246832.
4. Bataller A, Sasaki K, Urrutia S, Montalban-Bravo G, Bazinet A, Chien K, Hammond D, Bouligny IM, Swaminathan M, Issa G, Short N, Daver N, DiNardo CD, Kadia T, Jabbour E, Ravandi F, Roboz GJ, Savona M, Griffiths EA, McCloskey J, Odenike O, Oganesian A, Keer HN, Azab M, Kantarjian H, Garcia-Manero G. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study. Blood Cancer J 15(1):50, 2025. e-Pub 2025. PMID: 40164584.
5. Kugler E, Dasdemir E, Bataller A, Wang B, DiNardo CD, Daver N, Yilmaz M, Short NJ, Borthakur G, Kadia TM, Sasaki K, Hammond D, Bazinet A, Irajizad E, Thakral B, Pierce S, Reville P, Ravandi F, Abbas HA. Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions. Leuk Lymphoma:1-13, 2025. e-Pub 2025. PMID: 40164144.
6. Bazinet A, Bataller A, Kadia T, Daver N, Short NJ, Yilmaz M, Sasaki K, DiNardo CD, Borthakur GM, Issa G, Bouligny I, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian HM. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia. Cancer 131(6):e35813, 2025. e-Pub 2025. PMID: 40097915.
7. Urrutia S, Chien KS, Li Z, Bazinet A, Tang G, Garcia-Manero G. Cytogenetic annotation automation in myelodysplastic syndromes research databases. Blood Adv, 2025. e-Pub 2025. PMID: 39983082.
8. Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau S, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica, 2025. e-Pub 2025. PMID: 39973365.
9. Senapati J, Loghavi S, Marvin-Peek J, Garcia-Manero G, Kadia TM, Borthakur G, Daver N, Short NJ, Jain N, Issa GC, Haddad F, Hammond D, Chien K, Tang G, Thakral B, Montalban-Bravo G, Pemmaraju N, Bazinet A, Swaminathan M, Pierce S, Abbas HA, Reville P, Popat U, Shpall E, Champlin R, Jabbour E, Ravandi F, Kantarjian HM, DiNardo CD. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies. Am J Hematol, 2025. e-Pub 2025. PMID: 39921561.
10. Takaoka K, Komrokji R, Chien K, Montalban-Bravo G, Salman JB, Urrutia S, Bataller A, Bazinet A, Kekedjian J, Al Ali NH, Sallman D, Padron E, Xie Z, Kanagal-Shamanna R, Tang G, Yang H, Rodriguez-Sevilla JJ, Garcia-Manero G, Sasaki K. Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion. Leuk Res 150:107661, 2025. e-Pub 2025. PMID: 39938357.
11. Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Elliott M, Mangaonkar A, Matin A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Yates S, Sneider A, Dworkin E, Patel AA, Bazinet A, Senapati J, Bataller A, DiNardo C, Kadia T, Tefferi A. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. Am J Hematol 100(2):260-271, 2024. e-Pub 2024. PMID: 39671248.
12. Rodriguez-Sevilla, JJ, Ganan Gomez, I, Ma, F, Chien, KS, Del Rey, M, Loghavi, S, Montalban Bravo, G, Ademà Llobet, V, Wildeman, B, Kanagal Shamanna, R, Bazinet, A, Chifotides, H, Thongon, N, Calvo, X, Hernández, JM, Díez-Campelo, M, Garcia-Manero, G, Colla, S. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Nat Commun 15(1), 2024. e-Pub 2024. PMID: 38499526.
13. Senapati, J, Kantarjian, HM, Bazinet, A, Reville, PK, Short, NJ, Daver, N, Borthakur, G, Bataller, A, Jabbour, EJ, DiNardo, C, Haddad, FG, Sasaki, K, Popat, UR, Oran, B, Alousi, AM, Loghavi, S, Shpall, E, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. e-Pub 2024. PMID: 38809547.
14. Haddad FG, Sasaki K, Senapati J, Xiao L, Park G, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Ong F, Desikan S, Pemmaraju N, Loghavi S, Borthakur G, DiNardo C, Abbas HA, Short NJ, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia T. Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO Oncol Pract 20(12):OP2400027, 2024. e-Pub 2024. PMID: 39013130.
15. Bazinet, A, Wang, A, Li, X, Jia, F, Mo, H, Wang, W, Wang, S. Automated quantification of measurable residual disease in chronic lymphocytic leukemia using an artificial intelligence-assisted workflow. Cytometry B Clin Cytom 106(4):264-271, 2024. e-Pub 2024. PMID: 36824056.
16. Bataller, A, Gener-Ricos, G, Almanza-Huante, E, Chien, KS, Urrutia, S, Bazinet, A, Rodriguez-Sevilla, JJ, Hammond, DE, Sasaki, K, Takahashi, K, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, Kadia, TM, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv 8(11):2695-2706, 2024. e-Pub 2024. PMID: 38513082.
17. Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
18. Bazinet, A, Kantarjian, HM, Bataller, A, Pemmaraju, N, Borthakur, G, Chien, KS, Alvarado, Y, Bose, P, Jabbour, EJ, Yilmaz, M, DiNardo, C, Issa, GC, Montalban Bravo, G, Short, NJ, Sasaki, K, Bull-Linderman, D, Daver, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction. Lancet Haematol 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
19. Bazinet, A, Garcia-Manero, G, Short, NJ, Alvarado, Y, Bataller, A, Abuasab, T, Islam, R, Montalbano, K, Issa, GC, Maiti, A, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Montalban Bravo, G, Rausch, CR, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia. Lancet Haematol 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
20. Bazinet, A, Desikan, SP, Li, Z, Rodriguez-Sevilla, JJ, Venugopal, S, Urrutia, S, Montalban Bravo, G, Sasaki, K, Chien, KS, Hammond, DE, Kanagal Shamanna, R, Ganan Gomez, I, Kadia, TM, Borthakur, G, DiNardo, C, Daver, N, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clin Cancer Res 30(7):1319-1326, 2024. e-Pub 2024. PMID: 38300723.
21. Bataller, A, Montalban Bravo, G, Bazinet, A, Alvarado, Y, Chien, KS, Venugopal, S, Ishizawa, J, Hammond, DE, Swaminathan, M, Sasaki, K, Issa, GC, Short, NJ, Masarova, L, Daver, N, Kadia, TM, Colla, S, Qiao, W, Huang, X, Kanagal Shamanna, R, Hendrickson, S, Ravandi-Kashani, F, Jabbour, EJ, Kantarjian, HM, Garcia-Manero, G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
22. Bataller, A, Bazinet, A, DiNardo, C, Maiti, A, Borthakur, G, Daver, N, Short, NJ, Jabbour, EJ, Issa, GC, Pemmaraju, N, Yilmaz, M, Montalban Bravo, G, Takahashi, K, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. e-Pub 2024. PMID: 38113472.
23. Thompson, PA, Bazinet, A, Wierda, WG, Tam, CS, O'Brien, S, Saha, S, Peterson, CB, Plunkett, W, Keating, M. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up. Blood 142(21):1784-1788, 2023. e-Pub 2023. PMID: 37595283.
24. Bataller, A, Loghavi, S, Gerstein, YS, Bazinet, A, Sasaki, K, Chien, KS, Hammond, DE, Montalban Bravo, G, Borthakur, G, Short, NJ, Issa, GC, Kadia, TM, Daver, N, Tang, G, Quesada, AE, Patel, KP, Ravandi, F, Fiskus, WC, Mill, CP, Kantarjian, HM, Bhalla, K, Garcia-Manero, G, Oran, B, DiNardo, C. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
25. Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol 98(9):1383-1393, 2023. e-Pub 2023. PMID: 37334870.
26. Bazinet, A, Kadia, TM, Short, NJ, Borthakur, G, Wang, SA, Wang, W, Loghavi, S, Jorgensen, JL, Patel, KP, DiNardo, C, Daver, N, Alvarado, Y, Haddad, FG, Pierce, S, Gonzalez, GN, Maiti, A, Sasaki, K, Yilmaz, M, Thompson, PA, Wierda, WG, Garcia-Manero, G, Andreeff, M, Jabbour, EJ, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
27. Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. e-Pub 2023. PMID: 36458426.
28. Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
29. Bazinet, A, Heath, J, Chong, AS, Simo-Cheyou, ER, Worme, S, Polo, BR, Foulkes, WD, Caplan, S, Johnson, N, Orthwein, A, Mercier, F. Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline CHEK2 variant. Cold Spring Harb Mol Case Stud 7(3), 2021. e-Pub 2021. PMID: 33986034.
30. Bazinet, A, Rys, RN, Barry, A, Greenwood, CM, Young, YK, Mendoza, A, LaPorta, I, Wever, C, Mercier, F, Johnson, N. A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia. Leuk Lymphoma 62(10):2352-2359, 2021. e-Pub 2021. PMID: 34020575.
31. Estrada-Cuzcano A, Koenekoop RK, Senechal A, De Baere EB, de Ravel T, Banfi S, Kohl S, Ayuso C, Sharon D, Hoyng CB, Hamel CP, Leroy BP, Ziviello C, Lopez I, Bazinet A, Wissinger B, Sliesoraityte I, Avila-Fernandez A, Littink KW, Vingolo EM, Signorini S, Banin E, Mizrahi-Meissonnier L, Zrenner E, Kellner U, Collin RW, den Hollander AI, Cremers FP, Klevering BJ. BBS1 mutations in a wide spectrum of phenotypes ranging from nonsyndromic retinitis pigmentosa to Bardet-Biedl syndrome. Arch Ophthalmol 130(11):1425-32, 2012. e-Pub 2012. PMID: 23143442.
32. Majewski J, Wang Z, Lopez I, Al Humaid S, Ren H, Racine J, Bazinet A, Mitchel G, Braverman N, Koenekoop RK. A new ocular phenotype associated with an unexpected but known systemic disorder and mutation: novel use of genomic diagnostics and exome sequencing. J Med Genet 48(9):593-6, 2011. e-Pub 2011. PMID: 21862673.

Other Articles

1. Gener-Ricos G, Rodriguez-Sevilla JJ, Urrutia S, Bataller A, Bazinet A, Garcia-Manero G Advances in the management of higher-risk myelodysplastic syndromes: future prospects. Leuk Lymphoma 65(9):1233-1244, 2024. PMID: 38712556.
2. Bazinet, A, Kantarjian, HM Moving toward individualized target-based therapies in acute myeloid leukemia. Ann Oncol 34(2):141-151, 2023. PMID: 36423744.
3. Bazinet, A, Montalban Bravo, G New Approaches to Myelodysplastic Syndrome Treatment. Curr Treat Options Oncol 23(5):668-687, 2022. PMID: 35320468.
4. Bazinet, A, Kadia, TM Changing Paradigms in the Treatment of Acute Myeloid Leukemia in Older Patients. Clin Adv Hematol Oncol 20(1):37-46, 2022. PMID: 35060961.
5. Bazinet, A, Assouline, S A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’. Expert Rev Hematol 14(2):185-197, 2021. PMID: 33430671.
6. Bazinet, A, Popradi, G A general practitioner’s guide to hematopoietic stem-cell transplantation. Curr Oncol 26(3):187-191, 2019. PMID: 31285665.

Abstracts

1. Bazinet A, Daver N, Ravandi F, Short NJ, Yilmaz M, Ohanian M, Ishizawa J, Maiti A, DiNardo CD, Masarova L, Wierda WG, Chien KS, Jabbour E, Hammond D, Haddad FG, Sasaki K, Bataller A, Bull-Linderman D, Borthakur G, Garcia-Manero G, Kantarjian HM, Kadia TM. Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission. ASH Annual Meeting 2024.
2. Worme S, Jessa S, Poon W, Jankovic M, Galicia Vazquez G, Bazinet A, Fooks K, Iasenza I, Arreba-Tutusaus P, Eppert K, Ragoussis I, Wang YC, Johnson NA, Assouline SE, Kleinman C, Mercier F. Single-cell transcriptomic profiling of de novo and relapsed acute myeloid leukemia identifies a leukemic stemness program shared across diverse phenotypes. ASH Annual Meeting 2020.
3. Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Y, Chien K, Pemmaraju N, Takahashi K, Short N, Daver N, Issa G, Jain N, Ferrajoli A, Burger J, Bull-Linderman D, DiNardo C, Konopleva M, Garcia-Manero G, Sasaki K, Ravandi F, Kadia TM. A Phase II Study of 5-Azacitidine (AZA) and Venetoclax as Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission. ASH Annual Meeting 2021.
4. Bazinet A, Jabbour E, Kantarjian H, Chien K, DiNardo C, Ohanian M, Daver N, Kanagal-Shamanna R, Kadia TM, Takahashi K, Masarova L, Short N, Alvarado Y, Thompson P, Montalban Bravo G, Yilmaz M, Ravandi F, Kornblau S, Pemmaraju N, Schneider H, Mirabella B, Naqvi K, Garcia-Manero G. A Phase I/II Study of Venetoclax in Combination with 5-Azacitidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). ASH Annual Meeting 2021.
5. Bazinet A, Jabbour E, Kantarjian H, Chien K, DiNardo C, Ohanian M, Daver N, Kanagal-Shamanna R, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Thompson P, Montalban-Bravo G, Yilmaz M, Ravandi F, Konopleva M, Andreeff M, Kornblau S, Pemmaraju N, Hammond D, Schneider H, Mirabella B, Garcia-Manero G. Results of a phase 1 study of azacitidine combined with venetoclax for treatment-naïve and relapsed high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. EHA Annual Meeting 2022.
6. Haddad F, Sasaki K, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Senapati J, Ong F, Desikan SP, Short NJ, Pemmaraju N, Borthakur G, DiNardo CD, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kadia T. Outcomes of patients with newly diagnosed acute myeloid leukemia (AML) and hyperleukocytosis. ASCO Annual Meeting 2022.
7. Bazinet A, Kadia T, Short N, Borthakur G, Wang S, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad F, Pierce S, Andreeff M, Jabbour E, Konopleva M, Kantarjian H, Ravandi F. Achievement of measurable residual disease clearance is a stronger predictor of patient outcome than treatment intensity in newly diagnosed patients with acute myeloid leukemia. EHA Annual Meeting 2022.
8. Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Y, Chien K, Pemmaraju N, Takahashi K, Short NJ, Daver N, Issa G, Jain N, Bull-Linderman D, DiNardo C, Burger J, Ferrajoli A, Montalban-Bravo G, Garcia-Manero G, Sasaki K, Ravandi F, Kadia T. A Phase II Study of Azacitidine plus Venetoclax as Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-Up. ASH Annual Meeting 2022.
9. Bazinet A, Kantarjian H, Arani N, Popat U, DiNardo C, Daver N, Yilmaz M, Abbas H, Short NJ, Issa G, Jabbour E, Pierce S, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin R, Borthakur G, Ravandi F, Kadia T. Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years. ASH Annual Meeting 2022.
10. Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia. ASH Annual Meeting 2022.
11. Chien K, Urrutia S, Li Z, Kanagal-Shamanna R, Almanza E, Abuasab T, Gener Ricos G, Bataller A, Bazinet A, Montalban-Bravo G, Short N, Jabbour E, Kadia T, Ravandi F, Borthakur G, Hammond D, Swaminathan M, Sasaki K, Pierce S, Kantarjian H. Evolution of IPSS-M Risk Categories in Patients with Myelodysplastic Syndromes from Diagnosis to Hypomethylating Agent Failure. EHA Annual Meeting 2023.
12. Senapati J, Kantarjian H, Bazinet A, Reville P, Borthakur G, Daver N, DiNardo C, Bataller A, Jabbour E, Short N, Popat U, Alousi A, Shpall E, Garcia-Manero G, Ravandi F, Kadia T. Superior Outcomes after Allogeneic Stem Cell Transplantation (SCT) among Patients (Pts) ≥ 60 Years (Yrs) treated with Cladribine (CLAD), Low Dose Cytarabine (LDAC) Plus Venetoclax (Ven) for Newly Diagnosed Acute Myeloid Leukemia (AML). ASCO Annual Meeting 2023.
13. Bataller A, Venugopal S, Bazinet A, Montalban-Bravo G, Alvarado Y, Chien K, Issa G, Short N, Hammond D, Masarova L, Kadia T, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Phase 1/2 study of oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. EHA Annual Meeting 2023.
14. Bazinet A, Desikan SP, Li Z, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien K, Hammond D, Kanagal-Shamanna R, Mirabella B, Hendrickson S, Romero L, Colla S, Ganan-Gomez I, Rodriquez-Sevilla JJ, Kadia T, DiNardo C, Daver N, Jabbour E, Ravandi F, Kantarjian H, Garcia-Manero G. Clinical and molecular associations with outcomes in higher risk myelodysplastic syndromes treated with hypomethylating agents plus venetoclax. EHA Annual Meeting 2023.
15. Bazinet A, Arani N, Chien K, Hammond D, Kadia T, Borthakur G, Alvarado Y, Sasaki K, DiNardo C, Pemmaraju N, Masarova L, Short N, Yilmaz M, Daver N, Jabbour E, Ravandi F, Kanagal-Shamanna R, Pierce S, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Analysis of Response Rates and Outcomes in Erythroid-Predominant Myelodysplastic Syndromes (MDS) Treated with Venetoclax -Based Regimens. EHA Annual Meeting 2023.
16. Bataller A, Bazinet A, Borthakur G, Short NJ, Jabbour E, Takahashi K, Daver N, Issa GC, DiNardo CD, Pemmaraju N, Jain N, Montalban-Bravo G, Wierda WG, Ravandi F, Kantarjian HM, Kadia TM. CPX-351 with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase Ib Study. ASH Annual Meeting 2023.
17. Bazinet A, Kantarjian H, Ravandi F, Short NJ, Daver N, Ohanian M, Yilmaz M, Chien KS, Maiti A, DiNardo CD, Ishizawa J, Masarova L, Bull-Linderman D, Borthakur G, Jabbour E, Garcia-Manero G, Kadia T. Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study. ASH Annual Meeting 2023.
18. Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Y, Chien K, Pemmaraju N, Takahashi K, Short NJ, Daver N, Issa G, Jain N, Hammond D, Bull-Linderman D, DiNardo CD, Burger J, Ferrajoli A, Montalban-Bravo G, Sasaki K, Garcia-Manero G, Ravandi F, Kadia T. Azacitidine plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study. ASH Annual Meeting 2023.
19. Rodriguez Sevilla JJ, Ganan-Gomez I, Ma F, Chien KS, Montalban-Bravo G, Kanagal-Shamanna R, Loghavi S, Adema V, Thongon N, Bazinet A, Garcia-Manero G, Colla S. Myelodysplastic Syndrome Hematopoietic Stem Cells Can Undergo Differentiation Trajectory Rewiring to Escape Venetoclax Vulnerability. ASH Annual Meeting 2023.
20. Bazinet A, Garcia-Manero G, Short NJ, Alvarado Y, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Kantarjian H, Ravandi F. A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia. ASH Annual Meeting 2023.
21. Chien KS, Urrutia S, Li Z, Kanagal-Shamanna R, Adbelhakeem A, Abuasab T, Almanza E, Gener-Ricos G, Bataller A, Bazinet A, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Hammond DE, Swaminathan M, Sasaki K, Qin Dong X, Pierce S, Kantarjian HM, Garcia-Manero G. Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes. ASH Annual Meeting 2023.
22. Bataller A, Bazinet A, DiNardo CD, Borthakur G, Short NJ, Jabbour E, Takahashi K, Daver N, Issa GC, Pemmaraju N, Jain N, Montalban-Bravo G, Wierda WG, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax. ASH Annual Meeting 2023.
23. Bataller A, Bazinet A, Borthakur G, Short NJ, Jabbour E, Takahashi K, Daver N, Issa GC, DiNardo CD, Pemmaraju N, Jain N, Montalban-Bravo G, Wierda WG, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Cladribine with Low Dose Cytarabine and Venetoclax Alternated with Azacytidine and Venetoclax for Acute Myeloid Leukemia: Prognostic Analysis of a Phase 2 Clinical Trial. ASH Annual Meeting 2023.
24. Chien KS, Urrutia S, Li Z, Kanagal-Shamanna R, Adbelhakeem A, Abuasab T, Almanza E, Gener-Ricos G, Bataller A, Bazinet A, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Hammond DE, Swaminathan M, Sasaki K, Qin Dong X, Pierce S, Kantarjian HM, Garcia-Manero G. Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes. ASH Annual Meeting 2023.
25. Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Valero Y, Chien KS, Venugopal S, Ishizawa J, Hammond DE, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver N, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria. ASH Annual Meeting 2023.
26. Bazinet A, Dinardo CD, Arani N, Bataller A, Rausch CR, Maiti A, Swaminathan M, Daver N, Kadia TM, Ravandi F, Kantarjian HM, Chraibi S, Decroocq J, Pascal L, Lebon D, Bonnet S, Gauthier N, Pages A, De Botton S, Willekens C. A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia. ASCO Annual Meeting 2024.
27. Kugler E, Dasdemir E, Wang B, Bataller A, DiNardo CD, Daver NG, Yilmaz M, Short NJ, Kadia TM, Sasaki K, Bazinet A, Pierce S, Reville P, Ravandi F, Abbas H. Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions. ASCO Annual Meeting 2024.
28. Braish J, Li Z, Montalban-Bravo G, Sasaki K, Takahashi K, DiNardo CD, Hammond D, Swaminathan M, Bazinet A, Volpe VO, Weeks LD, Kantarjian HM, Garcia-Manero G, Chien KS. Genomic evolution of patients with myeloid neoplasms and known antecedent clonal hematopoiesis. ASCO Annual Meeting 2024.
29. Chien KS, Rodriguez-Sevilla JJ, Alvarado Valero Y, Montalban-Bravo G, Swaminathan M, Bazinet A, Kimberley J, Bodden K, Schneider H, Dong XQ, Pierce S, Huang X, Jabbour E, Kantarjian HM, Garcia-Manero G, Hammond D. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. ASCO Annual Meeting 2024.
30. Bataller A, Urrutia S, Sasaki K, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Issa G, Short N, Hammond D, Kadia T, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Al-Kali A, Griffiths EA, Savona M, Garcia-Manero G. Oral decitabine/cedazuridine with venetoclax versus oral decitabine/cedazuridine in high-risk myelodysplastic syndrome: A propensity score matched analysis. EHA Annual Meeting 2024.
31. Kugler E, Dasdemir E, Wang B, Bataller A, DiNardo CD, Daver NG, Yilmaz M, Short NJ, Kadia TM, Sasaki K, Bazinet A, Pierce S, Reville P, Ravandi F, Abbas H. Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions. EHA Annual Meeting 2024.
32. Chien K, Li Z, Urrutia S, Kanagal-Shamanna R, Abdelhakeem A, Abuasab T, Almanza E, Gener G, Bataller A, Bazinet A, Montalban-Bravo G, Short N, Kadia T, Ravandi F, Borthakur G, Hammond D, Swaminathan M, Sasaki K, Dong XQ, Pierce S, Kantarjian H, Garcia-Manero G. Risk stratification in hypomethylating agent-treated patients with myelodysplastic syndromes: a multivariate model. EHA Annual Meeting 2024.
33. Montalban-Bravo G, Short N, Alvarado-Valero Y, DiNardo C, Yilmaz M, Chien K, Hammond D, Bazinet A, Swaminathan M, Joseph J, Waukau J, Pierce S, Garcia-Manero G. Phase I/II study of seclidemstat, an LSD1 inhibitor, in combination with azacitidine for patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. EHA Annual Meeting 2024.
34. Chien K, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, Hammond D, Swaminathan M, Bazinet A, Kimberley J, Bodden K, Schneider H, Huang X, Jabbour E, Kantarjian H, Garcia-Manero G. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. EHA Annual Meeting 2024.
35. Chien K, Braish J, Li Z, Loghavi S, Montalban-Bravo G, Sasaki K, Takahashi K, DiNardo C, Bazinet A, Kantarjian H, Garcia-Manero G. Genomic evolution of patients with myeloid neoplasms and known antecedent clonal hematopoiesis. EHA Annual Meeting 2024.
36. Senapati J, DiNardo CD, Kadia TM, Khaire NS, Haddad FG, Loghavi S, Tang G, Deshmukh I, Jabbour JE, Issa GC, Short NJ, Yilmaz M, Hammond D, Borthakur G, Abbas HA, Bazinet A, Pierce S, Bhalla KN, Garcia-Manero G, Ravandi F, Kantarjian HM, Daver N. Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy. ASH Annual Meeting 2024.
37. Marvin-Peek J, Jen W, Short NJ, Issa GC, Yilmaz M, Montalban-Bravo G, Bazinet A, Sasaki K, Maiti A, Borthakur G, Hammond D, Chien KS, Abbas HA, Pemmaraju N, Garcia-Manero G, Jabbour E, Ravandi F, Kadia TM, Daver N, DiNardo CD. Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease. ASH Annual Meeting 2024.
38. Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Valero YA, DiNardo CD, Ravandi F, Pemmaraju N, Kadia TM, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal-Shamanna R, Pierce S, Meyer MA, Huang X, Garcia-Manero G. A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome. ASH Annual Meeting 2024.
39. Natu AA, Csizmar CM, Lasho TL, Kanagal-Shamanna R, Loghavi S, Bazinet A, Chien KS, Hammond D, Finke C, Al-Kali A, Alkhateeb HB, Gangat N, Mangaonkar AA, Saliba AN, Tefferi A, Garcia-Manero G, Kantarjian H, Montalban-Bravo G, Patnaik MM. Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML). ASH Annual Meeting 2024.
40. Bataller A, Kantarjian HM, Bazinet A, Senapati J, Borthakur G, Short NJ, Jabbour E, Takahashi K, Daver N, Issa GC, DiNardo CD, Pemmaraju N, Jain N, Montalban-Bravo G, Garcia-Manero G, Ravandi F, Kadia TM. Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. ASH Annual Meeting 2024.
41. Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Valero YA, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau SM, Kadia TM, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer MA, Huang X, Garcia-Manero G. A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome. ASH Annual Meeting 2024.
42. Arani N, Jen W, FRCPath, Bataller A, Bazinet A, Ravandi F, Daver N, Takahashi K, Loghavi S, Abbas HA, Almanza E, Montalban-Bravo G, Garcia-Manero G, DiNardo CD, Kantarjian HM, Kadia TM. Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia. ASH Annual Meeting 2024.
43. Swaminathan M, Fox DA, Chien KS, Montalban-Bravo G, Hammond D, Bazinet A, Pierce S, Hwang H, Huang X, Sasaki K, Kadia TM, Takahashi K, DiNardo CD, Jabbour E, Daver N, Kantarjian HM, Garcia-Manero G. Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds. ASH Annual Meeting 2024.
44. Bharathi V, Bataller A, Bazinet A, Borthakur G, Jabbour E, Daver N, Short NJ, Takahashi K, Issa GC, DiNardo CD, Pemmaraju N, Jain N, Montalban-Bravo G, Wierda WG, Ravandi F, Kantarjian HM, Kadia TM. Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). ASH Annual Meeting 2024.
45. Chien KS, Li Z, Lanino L, Al Ali NH, Urrutia S, Kanagal-Shamanna R, Abdelhakeem A, Abuasab T, Almanza E, Gener-Ricos G, Bataller A, Bazinet A, Campagna A, Maggioni G, Padron E, Xie Z, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Hammond D, Swaminathan M, Sasaki K, Dong XQ, Pierce S, Sallman D, Kantarjian HM, Della Porta MG, Garcia-Manero G, Komrokji RS. Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis. ASH Annual Meeting 2024.
46. Issa GC, Cuglievan B, Daver N, DiNardo CD, Farhat A, Short NJ, McCall D, Pike A, Tan S, Kammerer B, Marshal A, Yilmaz M, Kadia TM, Pemmaraju N, Ohanian M, Abbas HA, Maiti A, Bazinet A, Jabbour E, Sasaki K, Borthakur G, Montalban-Bravo G, Jain N, Valero YA, Ravandi F, Garcia-Manero G, Andreeff M, Kantarjian HM. Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML. ASH Annual Meeting 2024.
47. Marvin-Peek J, DiNardo CD, Jen W, Short NJ, Valero YA, Borthakur G, Daver N, Kugler E, Bazinet A, Abbas HA, Yilmaz M, Garcia-Manero G, Kantarjian HM, Kadia TM. Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax. ASH Annual Meeting 2024.
48. Senapati J, Kantarjian HM, Garcia-Manero G, Short NJ, Haddad FG, Daver N, DiNardo CD, Borthakur G, Jabbour JE, Pemmaraju N, Alousi AM, Shpall EJ, Bazinet A, Chien KS, Hammond D, Pierce S, Ravandi F, Kadia TM. Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation. ASH Annual Meeting 2024.
49. Uyanik MS, Garcia-Manero G, Maiti A, Ravandi F, Chien KS, Hammond D, Bazinet A, Schneider H, Hendrickson S, Pierce S, Kantarjian HM, Pemmaraju N, Montalban-Bravo G. Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes. ASH Annual Meeting 2024.
50. Kugler E, Kantarjian HM, Bazinet A, Jen W, Daver N, DiNardo CD, Short NJ, Senapati J, Borthakur G, Pemmaraju N, Issa GC, Bataller A, Reville PK, Garcia-Manero G, Ravandi F, Kadia TM. Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission. ASH Annual Meeting 2024.
51. Burger JA, Kim E, Jayachandran G, Lopez W, Issa GC, Yilmaz M, Swaminathan M, Ishizawa J, Bazinet A, Valero YA, Jain N, Wierda WG, Ferrajoli A. A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia. ASH Annual Meeting 2024.
52. Montalban-Bravo G, Chien KS, Loghavi S, Kanagal-Shamanna R, Natu AA, Gurney M, Bazinet A, Hammond D, Borthakur G, Swaminathan M, DiNardo CD, Kadia TM, Ravandi F, Daver N, Pemmaraju N, Issa GC, Lasho TL, Finke C, Al-Kali A, Csizmar CM, Alkhateeb HB, Gangat N, Mangaonkar AA, Tefferi A, Kantarjian H, Garcia-Manero G, Patnaik MM. Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia. ASH Annual Meeting 2024.
53. Marvin-Peek J, Kantarjian HM, Jen W, Borthakur G, Daver N, Maiti A, Short NJ, Kornblau SM, Pemmaraju N, Kugler E, Bazinet A, Valero YA, Abbas HA, Garcia-Manero G, Popat U, Shpall EJ, Ravandi F, DiNardo CD, Kadia TM. Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax. ASH Annual Meeting 2024.
54. Bazinet A, Garcia-Manero G, Bataller A, Valero YA, Yilmaz M, Jabbour E, Montalban-Bravo G, Pemmaraju N, Issa GC, Short NJ, Kadia TM, Jain N, Masarova L, Daver N, Hammond D, Borthakur G, Maiti A, Takahashi K, Chien KS, Kornblau SM, Abbas HA, Ohanian M, Senapati J, DiNardo CD, Kantarjian HM, Ravandi F. Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy. ASH Annual Meeting 2024.
55. Lanino L, Hunter AM, Gagelmann N, Robin M, Sala C, Dall'Olio D, Gurnari C, Dall'Olio L, Wang Y, Pleyer L, Xicoy B, Montalban-Bravo G, Shih L, Haque T, Abdel-Wahab O, Geissler K, Bataller A, Bazinet A, Meggendorfer M, Casetti IC, Sauta E, Travaglino E, Palomo L, Zamora L, Quintela D, Jerez A, Cornejo E, Martin PG, Díaz-Beyá M, Pita AA, Roldan V, Fiallo Suarez DV, Velasco EC, Calabuig M, Such E, Sanz G, Kubasch AS, Castilla-Llorente C, Bulabois C, Souchet L, Awada H, Bernardi M, Chiusolo P, Curti A, Giaccone L, Onida F, Borin LM, Passamonti F, Diral E, Vucinic V, Bergonzi GM, Voso MT, Hou H, Chou W, Yao C, Lin C, Tien H, Campagna A, Ubezio M, Russo A, Todisco G, Maggioni G, Tentori CA, Buizza A, Asti G, Zampini M, Riva E, Delleani M, Consagra A, Ficara F, Santoro A, Carota L, Sanavia T, Rollo C, Kiwan A, VanOudenhove J, Fariselli P, Al Ali NH, Sallman D, Kern W, Garcia-Manero G, Thota S, Griffiths EA, Follo MY, Finelli C, Platzbecker U, Sole F, Diez-Campelo M, Maciejewski J, Bejar R, Thol FR, Kröger N, Fenaux P, Itzykson R, Graubert TA, Fontenay M, Zeidan AM, Komrokji RS, Santini V, Haferlach T, Germing U, D'Amico S, Castellani G, Patnaik MM, Solary E, Padron E, Della Porta MG. A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML). ASH Annual Meeting 2024.
56. Csizmar CM, Natu AA, Gurney M, Kanagal-Shamanna R, Loghavi S, Bazinet A, Chien KS, Hammond D, Lasho TL, Finke C, Al-Kali A, Alkhateeb HB, Gangat N, Mangaonkar AA, Saliba AN, Tefferi A, Garcia-Manero G, Kantarjian H, Montalban-Bravo G, Patnaik MM. Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML). ASH Annual Meeting 2024.

Letters to the Editor

1. Bouligny, IM, Montalban-Bravo, G, Sasaki, K, Daver, N, Jabbour, EJ, Alvarado, Y, DiNardo, CD, Ravandi, F, Borthakur, G, Pemmaraju, N, Kadia, TM, Masarova, L, Takahashi, K, Andreeff, M, Bazinet, A, Yang, H, Kanagal, R, Pierce, S, Meyer, M, Huang, X, Garcia-Manero, G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39: 524-528, 2025.
2. Chien KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, Hammond DE, Swaminathan M, Bazinet A, Kimberley J, Bodden K, Schneider H, Dong XQ, Pierce SA, Huang X, Jabbour EJ, Kantarjian HM, Garcia-Manero G. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. Leuk Res 147: 107602, 2024.
3. Bataller, A, DiNardo, C, Bazinet, A, Daver, N, Maiti, A, Borthakur, G, Short, NJ, Sasaki, K, Jabbour, EJ, Issa, GC, Pemmaraju, N, Yilmaz, M, Montalban Bravo, G, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99: 792-796, 2024.
4. Kim, K, Bazinet, A, Loghavi, S, Konopleva, M, Bhalla, K, Daver, N, Khoury, J, Kadia, TM, Wilson, NR, Curry, JL, Heberton, MM, Miller, D, Pierce, S, Borthakur, G, Pemmaraju, N. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. Leuk Res 119, 2022.